Downregulation of GIMAP1-GIMAP5 may disrupt immune surveillance in the tumor microenvironment, potentially impairing T-cell function or promoting immune evasion, which could accelerate tumor progression and worsen prognosis. This evidence concerns the gene GIMAP1 and neoplasm.